Artelo Biosciences, Inc. (ARTL), a clinical-stage biopharmaceutical company, announced the closing of its underwritten public offering of 640,924 shares of common stock at $4.40 per share and pre-funded warrants to purchase 40,894 shares at $4.399 per warrant.
The gross proceeds totaled approximately $3 million before deducting fees and expenses. The company also granted underwriters a 45-day option to purchase up to 102,272 additional shares to cover over-allotments.
R. F. Lafferty & Co., Inc. served as sole book-running manager and underwriter. The securities were issued under Artelo's effective shelf registration statement on Form S-3, with the final prospectus supplement filed with the SEC on September 5, 2025.
Friday ARTL closed at $4.51, up 3.68%, and showed no after-hours movement on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.